Management of pediatric central nervous system demyelinating disorders: Consensus of United States neurologists

Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.

Original languageEnglish (US)
Pages (from-to)675-682
Number of pages8
JournalJournal of child neurology
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Central Nervous System Diseases
Demyelinating Diseases
Pediatrics
Physicians' Practice Patterns
Delphi Technique
Therapeutics
Methylprednisolone
Interferons
Multiple Sclerosis
Neurologists
Research

Keywords

  • acute disseminated encephalomyelitis
  • multiple sclerosis
  • optic neuritis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society (2011). Management of pediatric central nervous system demyelinating disorders: Consensus of United States neurologists. Journal of child neurology, 26(6), 675-682. https://doi.org/10.1177/0883073810395141

Management of pediatric central nervous system demyelinating disorders : Consensus of United States neurologists. / Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society.

In: Journal of child neurology, Vol. 26, No. 6, 01.06.2011, p. 675-682.

Research output: Contribution to journalArticle

Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society 2011, 'Management of pediatric central nervous system demyelinating disorders: Consensus of United States neurologists', Journal of child neurology, vol. 26, no. 6, pp. 675-682. https://doi.org/10.1177/0883073810395141
Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society. Management of pediatric central nervous system demyelinating disorders: Consensus of United States neurologists. Journal of child neurology. 2011 Jun 1;26(6):675-682. https://doi.org/10.1177/0883073810395141
Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society. / Management of pediatric central nervous system demyelinating disorders : Consensus of United States neurologists. In: Journal of child neurology. 2011 ; Vol. 26, No. 6. pp. 675-682.
@article{e6112e3522c341a095549c24c8063066,
title = "Management of pediatric central nervous system demyelinating disorders: Consensus of United States neurologists",
abstract = "Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.",
keywords = "acute disseminated encephalomyelitis, multiple sclerosis, optic neuritis",
author = "{Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society} and Waldman, {Amy T.} and Gorman, {Mark P.} and Rensel, {Mary R.} and Austin, {Tracy E.} and Hertz, {Deborah P.} and Kuntz, {Nancy L.} and G. Acsadi and G. Alper and K. Bashir and N. Bass and A. Belman and D. Chabas and T. Chitnis and M. Cohen and J. Corboy and A. Fernandez and J. Fleming and Elliot Frohman and B. Giesser and J. Hahn and M. Islam and D. Kantor and M. Kaufman and L. Krupp and M. Lloyd and T. Lotze and S. Lucas and S. Mar and D. Mattson and D. Michelson and W. Mitchell and M. Moodley and H. Moses and J. Ness and C. Parker and M. Rodriguez and J. Rose and J. Rubin and J. Strober and A. Vanderver and B. Weinstock-Guttman and B. Weissman and J. Wollack and A. Yeh",
year = "2011",
month = "6",
day = "1",
doi = "10.1177/0883073810395141",
language = "English (US)",
volume = "26",
pages = "675--682",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Management of pediatric central nervous system demyelinating disorders

T2 - Consensus of United States neurologists

AU - Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society

AU - Waldman, Amy T.

AU - Gorman, Mark P.

AU - Rensel, Mary R.

AU - Austin, Tracy E.

AU - Hertz, Deborah P.

AU - Kuntz, Nancy L.

AU - Acsadi, G.

AU - Alper, G.

AU - Bashir, K.

AU - Bass, N.

AU - Belman, A.

AU - Chabas, D.

AU - Chitnis, T.

AU - Cohen, M.

AU - Corboy, J.

AU - Fernandez, A.

AU - Fleming, J.

AU - Frohman, Elliot

AU - Giesser, B.

AU - Hahn, J.

AU - Islam, M.

AU - Kantor, D.

AU - Kaufman, M.

AU - Krupp, L.

AU - Lloyd, M.

AU - Lotze, T.

AU - Lucas, S.

AU - Mar, S.

AU - Mattson, D.

AU - Michelson, D.

AU - Mitchell, W.

AU - Moodley, M.

AU - Moses, H.

AU - Ness, J.

AU - Parker, C.

AU - Rodriguez, M.

AU - Rose, J.

AU - Rubin, J.

AU - Strober, J.

AU - Vanderver, A.

AU - Weinstock-Guttman, B.

AU - Weissman, B.

AU - Wollack, J.

AU - Yeh, A.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.

AB - Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.

KW - acute disseminated encephalomyelitis

KW - multiple sclerosis

KW - optic neuritis

UR - http://www.scopus.com/inward/record.url?scp=79957591907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957591907&partnerID=8YFLogxK

U2 - 10.1177/0883073810395141

DO - 10.1177/0883073810395141

M3 - Article

C2 - 21518802

AN - SCOPUS:79957591907

VL - 26

SP - 675

EP - 682

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 6

ER -